Skip to main content
. 2016 Aug 18;115(7):776–783. doi: 10.1038/bjc.2016.249

Table 1. Clinical characteristics of breast cancer patients according to BRCA2 mutation status (period of diagnosis 1935–2012).

Characteristic Non-carriers BRCA2 mutation P-value
Mutation status analysed (n) 555a 279a  
Year of birth, mean (range) 1935 (1873–1980) 1935 (1874–1977) 0.93
Year of diagnosis, mean (range) 1985 (1935–2012) 1985 (1935–2012) 0.86
Age at diagnosis, mean (range) 49.4 (26–82) 49.5 (21–82) 0.93
Second inv. contralat. breast cancer 6.7% 18.6% <0.001
Morphology (n)      
Ductal 90.7% 87.8% 0.21
Lobular 9.3% 12.2%  
Other and unknown (n) 72 26  
Size      
Mean (mm) 23.9 (1–110) 27.3 (1–110) 0.01
T1⩽20 mm 55.4% 47.1%  
T2>20 mm and⩽50 mm 38.8% 44.2% 0.09
T3>50 mm 5.8% 8.7%  
Unknown (n) 89 48  
Nodal involvement      
No 57.0% 44.5% 0.001
Yes 43.0% 55.5%  
Unknown (n) 55 16  
Detailed information (n) 425 220  
  0 positive nodes 66.8% 53.2%  
  1–3 positive nodes 23.1% 24.1% <0.001
  4–9 positive nodes 6.6% 12.7%  
  ⩾10 positive nodes 3.5% 10.0%  
Grade      
1–well differentiated 26.2% 12.0%  
2–moderately differentiated 46.8% 52.1% <0.001
3–poorly differentiated 26.9% 36.0%  
Unknown (n) 42 12  
ER status      
Negative 29.8% 24.4%  
Positive 70.2% 75.6% 0.11
Unknown (n) 52 17  

Abbreviation: ER=oestrogen receptor.

a

Twenty-one patients who had metastatic disease at diagnosis were excluded, leaving 279 mutation carriers and 555 non-carriers for analyses.